Why Cancer Drugs Don’t Work for Everyone: MIT’s Eye-Opening Discovery

 

Scientists at MIT discovered why cancer drugs like TKIs don’t work for everyone: tumors activate a hidden SRC backup pathway. Learn what this means and 7 practical steps to improve outcomes with combination therapy.

**Scientists Discover Why Cancer Drugs Don’t Work for Everyone**  

*By the Human Lab Team | March 2026*

Hey there, fellow humans navigating this wild ride we call life. At Human Lab, we don’t just report breakthroughs—we sit with the real questions they raise. Like: Why do some cancer drugs that should save lives only work for some people? You’ve probably heard the stories—someone’s tumor shrinks dramatically while their friend’s barely budges. It’s frustrating, heartbreaking, and until recently, mostly a mystery.

This week, scientists at MIT gave us a clearer answer. In a study published just days ago, researchers figured out that many tumors have a built-in “backup plan”—a survival pathway that kicks in the moment the main target of the drug gets blocked. The drugs in question are tyrosine kinase inhibitors (TKIs), powerful targeted therapies used for lung cancer, leukemia, melanoma, and more. They’re designed to shut down overactive proteins (like EGFR, MET, or ALK) that drive cancer growth. For 40–80% of patients who *should* respond, they do… but not everyone, and not forever.

Here’s the human-scale version: Imagine a cancer cell as a factory with a main power switch (the tyrosine kinase). The drug flips that switch off. Great, right? Except some cells have a hidden generator—run by a family of proteins called SRC kinases—that keeps the lights on. The factory keeps humming. The tumor survives. And the patient doesn’t get the result they hoped for.

The MIT team used a technique called phosphoproteomics (basically, mapping which proteins are “turned on” by measuring phosphate tags) on lung cancer cell lines from real patients. They saw it clearly: even *before* treatment started, the resistant cells already had this SRC backup pathway lit up. It wasn’t something the drug created later—it was already there, hardwired.

Lead researcher Cameron Flower put it plainly: “Even before the therapy begins, the cells are in a state that intrinsically is resistant to the drug.” Forest White, another key scientist on the team, added that this pathway seems to protect cells against a wide range of therapies, including some chemotherapies.

The good news? This isn’t just another “cancer is complicated” headline. It’s actionable. The team showed that pairing TKIs with drugs that block the SRC pathway dramatically increases cancer cell death in lab tests. Clinical trials are already underway—one combining the lung cancer drug osimertinib with an SRC inhibitor. Similar approaches are being explored for pancreatic cancer and beyond. Phosphoproteomics on a simple biopsy could even help doctors spot who needs the combo from day one.

This discovery feels like a turning point because it treats resistance not as random bad luck, but as a predictable biological feature we can now see and outsmart. It shifts the conversation from “Why me?” to “What’s the full map of *this* tumor?”

At Human Lab, we believe science should serve the humans it’s meant to help. So we’re not stopping at the headline. Here are **7 practical steps** you (or someone you love) can take right now to turn this knowledge into better outcomes:

1. **Ask for deeper profiling upfront.** Don’t settle for basic genetic testing. Request phosphoproteomics or advanced tumor mapping if available (or ask your oncologist about trials that include it). Knowing about backup pathways like SRC early changes the game.

2. **Talk combination therapy.** Bring this MIT study to your next appointment. Ask: “Could adding an SRC inhibitor (or similar) make my TKI work better?” Clinical trials are open—being informed gets you in the conversation.

3. **Get a second (or third) opinion at a research center.** Places like MIT’s Koch Institute, major cancer centers, or hospitals running TKI + SRC trials often have the latest tools. One extra consult can open doors to personalized plans.

4. **Support your body’s terrain.** While science targets the cancer, lifestyle still matters. Eat anti-inflammatory foods, move daily, prioritize sleep, and manage stress. These don’t replace drugs but help your system handle treatment and reduce inflammation that can fuel resistance.

5. **Join or advocate for the right trials.** Search clinicaltrials.gov for “osimertinib SRC” or similar combos. If you’re not eligible yet, share the study with patient advocacy groups—they’re pushing to make these tests and combos standard faster.

6. **Track and report symptoms honestly.** Early signs of resistance matter. Keep a simple journal of energy, side effects, and scan results. Share it with your team—data helps them spot when the backup pathway might be activating.

7. **Spread the word and fund the future.** Share this story with friends, family, or online communities. Donate to or volunteer with organizations funding resistance research (Koch Institute, Cancer Research UK, etc.). Every voice and dollar pushes these combo strategies from lab to clinic faster.

Cancer is still tough, but discoveries like this remind us it’s not unbeatable. The backup pathway isn’t a dead end—it’s a map. By understanding it, we move closer to treatments that work for *more* of us, not just some of us.

If this resonates with your journey, drop a note in the comments or share your experience. At Human Lab, we’re in this together—curious humans chasing better answers for the humans we love.

Stay hopeful, stay informed.  

—The Human Lab Team

*(Sources: MIT News, PNAS study. Always consult your doctor for personal medical advice—this is for education and empowerment only.)*